Our major aim is to establish optimal diagnostic and treatment algorithm for the patients with aggressive B-cell lymphomas. This includes designing, coordinating and conducting a randomized multicenter biomarker guided clinical trial. Crucial other activities include comprehensive characterization of these lymphomas, and establishment of a blood sample (liquid biopsy) based platform for diagnostics, risk stratification and follow-up, and another platform for drug sensitivity and resistant testing. Lastly, we will follow patients' wellbeing by launching electronic patient reported outcome based follow up program.

2021

2023